These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37596437)

  • 21. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease.
    Rani S; Dhar SB; Khajuria A; Gupta D; Jaiswal PK; Singla N; Kaur M; Singh G; Barnwal RP
    Cell Mol Neurobiol; 2023 Aug; 43(6):2491-2523. PubMed ID: 36847930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
    Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
    Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer's Disease and Correlation with Cerebral Hypoperfusion Pattern.
    Mazzon G; Ajčević M; Cattaruzza T; Menichelli A; Guerriero M; Capitanio S; Pesavento V; Dore F; Sorbi S; Manganotti P; Marini A
    Curr Alzheimer Res; 2019; 16(6):483-494. PubMed ID: 31057108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease.
    More SS; Beach JM; McClelland C; Mokhtarzadeh A; Vince R
    ACS Chem Neurosci; 2019 Nov; 10(11):4492-4501. PubMed ID: 31603648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease.
    Singh AK; Verma S
    Indian J Ophthalmol; 2020 Apr; 68(4):555-561. PubMed ID: 32174567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative phosphoproteomic analyses of the inferior parietal lobule from three different pathological stages of Alzheimer's disease.
    Triplett JC; Swomley AM; Cai J; Klein JB; Butterfield DA
    J Alzheimers Dis; 2016; 49(1):45-62. PubMed ID: 26444780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study.
    van de Sande N; Ramakers IHGB; Visser PJ; Verhey FRJ; Verbraak FD; Bouwman FH; Berendschot TTJM; Nuijts RMMA; Webers CAB; Gijs M
    BMC Neurol; 2023 Aug; 23(1):293. PubMed ID: 37543602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
    Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonlinear changes in delayed functional network topology in Alzheimer's disease: relationship with amyloid and tau pathology.
    Mijalkov M; Veréb D; Canal-Garcia A; Hinault T; Volpe G; Pereira JB;
    Alzheimers Res Ther; 2023 Jun; 15(1):112. PubMed ID: 37328909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinal ganglion cell dysfunction in preclinical Alzheimer's disease: an electrophysiologic biomarker signature.
    Asanad S; Felix CM; Fantini M; Harrington MG; Sadun AA; Karanjia R
    Sci Rep; 2021 Mar; 11(1):6344. PubMed ID: 33737516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimer's disease.
    Bevan RJ; Hughes TR; Williams PA; Good MA; Morgan BP; Morgan JE
    Acta Neuropathol Commun; 2020 Dec; 8(1):216. PubMed ID: 33287900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.